Breaking News Instant updates and real-time market news.

REGN

Regeneron

$366.00

-8.53 (-2.28%)

07:02
11/29/17
11/29
07:02
11/29/17
07:02

Regeneron and Decibel to collaborate in hearing therapeutics

Regeneron Pharmaceuticals and Decibel Therapeutics announced a collaboration to discover and develop new potential therapeutics to protect, repair, and restore hearing. Decibel is establishing a leadership position in hearing therapeutics by building the world's first comprehensive, integrated drug discovery, translational research, and drug development platform for hearing loss and tinnitus. Regeneron will provide Decibel with broad access to its proprietary suite of technologies to support Decibel's goal of discovering important new medicines for hearing. Regeneron will also directly participate in and provide financial support for Decibel's research and development efforts, both through R&D funding payments and a strategic equity investment in Decibel. Decibel retains worldwide development and commercialization rights to any products discovered in the collaboration and will pay Regeneron tiered royalties based on net sales. Further financial terms were not disclosed

  • 09

    Dec

REGN Regeneron
$366.00

-8.53 (-2.28%)

11/13/17
MSCO
11/13/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees limited near-term impact on Regeneron from Novartis data
Morgan Stanley analyst Matthew Harrison noted that Novartis (NVS) presented RTH258 data at the American Academy of Ophthalmology meeting that did show the potential for a commercial "hook," namely an ability to "dry out" hard to treat patients. However, an FDA filing is not expected until the second half of 2018 and key safety details are still needed for a more accurate determination of brolucizumab's possible commercial impact, said Harrison, who sees limited near-term impact on Regeneron (REGN) from the data on the Eylea competitor. He keeps an Equal Weight rating on Regeneron shares.
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.
11/28/17
BOFA
11/28/17
NO CHANGE
BOFA
Equity Residential, Regeneron removed from US 1 List at BofA/Merrill
11/28/17
BMOC
11/28/17
NO CHANGE
Target $444
BMOC
Market Perform
Regeneron price target lowered to $444 from $479 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $444, saying the Phase 2 trial failure of Eylea injection with Ang2 in AMD and DME "eliminates a potential growth source". The analyst notes that while the expectations for Ang2 were low, the setback is another example of long-term risks to Regeneron's core business. Luchini keeps his Market Perform rating, saying investors' focus now shifts to Praluent ODYSSEY outcomes data in early 2018, PANORAMA Phase III data of Eylea in diabetic retinopathy in the first half of next year, and updated Phase II data for REGN2810 in CSCC expected in the current quarter to be followed by potential filing in Q1 and proof-of-concept Phase I data for REGN3500.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.